Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 47 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cetirizine Clear all
Completed Phase 4 Interventional Accepts healthy volunteers

Single Center, Randomized, Double-Blind,Crossover Study Comparing Effects Of Single-Dose Fexofenadine HCl 180 mg, Cetirizine 10 mg, and Placebo on Cognitive Performance in Naval Flight Personnel

NCT00637455
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
fexofenadine HCl
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 11, 2011 · Synced Oct 19, 2026, 4:27 PM EDT
Completed Phase 2 Interventional Results available

Personalized Treatment Algorithms for Difficult-to-treat Asthma

NCT04179461
View directory record Official record
Conditions
Asthma in Children
Interventions
Cholecalciferol, antihistamine, Azithromycin, emollient cream, Fluticasone Propionate, Asthma Controller Medication
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 20, 2021 · Synced Oct 19, 2026, 4:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Cetirizine HCl 10 mg Tablets Under Fasting Conditions

NCT00864279
View directory record Official record
Conditions
Healthy
Interventions
Cetirizine Hydrochloride 10 mg tablets, single dose, Zyrtec® 10 mg tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Morrisville, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Oct 19, 2026, 4:27 PM EDT
Completed Phase 3 Interventional Results available

A Multi-Center Study Evaluating the Safety of AC-170 0.24%

NCT02132169
View directory record Official record
Conditions
Atopic Disease (Including Allergic Conjunctivitis)
Interventions
Drug: AC-170 0.24%, AC-170 0%
Drug
Lead sponsor
Aciex Therapeutics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
512 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 19, 2026, 4:27 PM EDT
Withdrawn Phase 4 Interventional

Cetirizine and Famotidine for COVID-19

NCT04836806
View directory record Official record
Conditions
Covid19
Interventions
Cetirizine and Famotidine, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 20, 2021 · Synced Oct 19, 2026, 4:27 PM EDT
Completed Phase 3 Interventional Results available

Clinical Trial Comparing JDP-205 to Diphenhydramine Injection for the Treatment of Acute Urticaria

NCT02935699
View directory record Official record
Conditions
Acute Urticaria
Interventions
Test Drug (JDP-205), Active Control (Diphenhydramine)
Drug
Lead sponsor
JDP Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Cincinnati, Ohio • Philadelphia, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 19, 2026, 4:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Cetirizine HCl Tablets 10 mg and Zyrtec® Tablets 10 mg

NCT00650065
View directory record Official record
Conditions
Healthy
Interventions
Cetirizine HCl Tablets 10 mg, Zyrtec® Tablets 10 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 19, 2026, 4:27 PM EDT
Completed Phase 1Phase 2 Interventional

NVG-291 in Spinal Cord Injury Subjects

NCT05965700
View directory record Official record
Conditions
Spinal Cord Injuries, Chronic Spinal Cord Injury, Subacute Spinal Cord Injury
Interventions
NVG-291, Placebo Injection
Drug
Lead sponsor
NervGen Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 19, 2026, 4:27 PM EDT
Completed Phase 3 Interventional Results available

A Multi-Center, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution

NCT02756624
View directory record Official record
Conditions
Healthy Subjects
Interventions
AC-170 0.24%, AC-170 Vehicle
Drug
Lead sponsor
Nicox Ophthalmics, Inc.
Industry
Eligibility
2 Years and older
Enrollment
516 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 19, 2026, 4:27 PM EDT
Terminated Phase 3 Interventional Results available

Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris

NCT02613910
View directory record Official record
Conditions
Pemphigus
Interventions
Ofatumumab, Acetaminophen/paracetamol, Antihistamine (cetirizine or equivalent), Prednisone/Prednisolone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Los Angeles, California • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 19, 2026, 4:27 PM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine

NCT04189588
View directory record Official record
Conditions
Oncology Patients Receiving Chemotherapy
Interventions
Cetirizine HCl 10 mg/mL, Diphenhydramine 50 mg/mL, anti-CD20 such as Rituximab or Paclitaxel
Drug
Lead sponsor
TerSera Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
7
States / cities
Napa, California • Rancho Mirage, California • Santa Rosa, California + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2023 · Synced Oct 19, 2026, 4:27 PM EDT
Terminated Phase 3 Interventional Results available

Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial

NCT05946551
View directory record Official record
Conditions
COVID-19
Interventions
Cetirizine, Famotidine, Cetirizine Placebo, Famotidine Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 19, 2026, 4:27 PM EDT
Withdrawn Phase 3 Interventional

Antihistamines in the Treatment of Irritable Bowel Syndrome With Diarrhea

NCT04612803
View directory record Official record
Conditions
Irritable Bowel Syndrome, Dermatographism, Post-prandial Diarrhea
Interventions
Antihistamine, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 19, 2026, 4:27 PM EDT
Completed Phase 4 Interventional Results available

Is Levocetirizine Less Sedating Than Cetirizine?

NCT00826943
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Cetirizine, Levocetirizine, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 77 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 20, 2014 · Synced Oct 19, 2026, 4:27 PM EDT
Completed Phase 4 Interventional Results available

A Comparator Study of Fluticasone Propionate Nasal Spray Verses (vs) Cetirizine in the Treatment of Seasonal Allergic Rhinitis

NCT01916226
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial and Seasonal
Interventions
FPNS, FPNS Placebo, Cetirizine, Cetirizine Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
31
States / cities
Little Rock, Arkansas • Denver, Colorado • Aventura, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Oct 19, 2026, 4:27 PM EDT
Completed Phase 3 Interventional Results available

A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)

NCT01551056
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
AC-170 0.24%, AC-170 0%
Drug
Lead sponsor
Aciex Therapeutics, Inc.
Industry
Eligibility
10 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 7, 2017 · Synced Oct 19, 2026, 4:27 PM EDT
Completed Phase 3 Interventional Results available

A Multi-Center, Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle

NCT01881113
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
AC-170 0.24%, AC-170 0%
Drug
Lead sponsor
Aciex Therapeutics, Inc.
Industry
Eligibility
10 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 9, 2017 · Synced Oct 19, 2026, 4:27 PM EDT
Not yet recruiting Phase 3 Interventional

Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project

NCT07472413
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Cetirizine, Diphenhydramine
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 19, 2026, 4:27 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Cetirizine Hydrochloride 10mg Tablets Under Fasting Conditions

NCT00776139
View directory record Official record
Conditions
Healthy
Interventions
Cetirizine Hydrochloride 10 mg tablet
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2008 · Synced Oct 19, 2026, 4:27 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy of AC-170 for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge (CAC) Model

NCT01332188
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
AC-170 0.05%, AC-170 0.1%, AC-170 0.24%, AC-170 0%
Drug
Lead sponsor
Aciex Therapeutics, Inc.
Industry
Eligibility
10 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Oct 19, 2026, 4:27 PM EDT
Completed Phase 1 Interventional

A Single-Center, Open-Label, Study of the Plasma Pharmacokinetics and Safety of AC-170 0.24%

NCT02173249
View directory record Official record
Conditions
Healthy
Interventions
AC 170 0.24%
Drug
Lead sponsor
Aciex Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Oct 19, 2026, 4:27 PM EDT
Completed Phase 3 Interventional

Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis

NCT01484119
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
ACT-129968, Placebo, Cetirizine
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
12 Years to 76 Years
Enrollment
630 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
7
States / cities
Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2018 · Synced Oct 19, 2026, 4:27 PM EDT
Completed Phase 3 Interventional Results available

Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab

NCT04175834
View directory record Official record
Conditions
Multiple Sclerosis, Infusion Reaction
Interventions
cetrizine, diphenhydramine
Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 4, 2024 · Synced Oct 19, 2026, 4:27 PM EDT
Completed Phase 1 Interventional

A Comparison of the Safety and Comfort of AC-170

NCT01495338
View directory record Official record
Conditions
Normal Ocular Health
Interventions
AC-170 0.17%, AC-170 0.24% (Formulation 1), AC-170 0.24% (Formulation 2), Olopatadine hydrochloride 0.2%/Tears Naturale II
Drug
Lead sponsor
Aciex Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 14, 2017 · Synced Oct 19, 2026, 4:27 PM EDT